Prevention Of Recurrence Of Atrial Fibrillation

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00041496

Enrollment

520

Registered

2002-07-12

Start date

2001-11-30

Completion date

2003-12-31

Last updated

2014-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrillation, Atrial

Keywords

symptomatic atrial fibrillation, persistent atrial fibrillation

Brief summary

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Interventions

DRUGSB-207266

White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

OTHERPlacebo

Placebo to match SB-207266

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Symptomatic persistent atrial fibrillation requiring DC cardioversion. * Duration of AF \>48 hrs. \<6 months

Exclusion criteria

* Concomitant Class I and/or III anti-arrhythmic drugs. * Amiodarone treatment within 3 months of the study. * Other inclusion or

Design outcomes

Primary

Measure	Time frame
Time-to-first symptomatic AF (atrial fibrillation)	Up to 26 Weeks

Secondary

Measure	Time frame
Time to first symptomatic or detected asymptomatic AF; spontaneous reversion to sinus rhythm prior to cardioversion	Up to 26 Weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026